Listen to the power of Olink's scalability from the customer perspective

Original broadcast date: Thursday, 01 April 2021

Speaker: Ferhan Qureshi, Vice President – Biomarker Product Development

Care for Multiple Sclerosis patients relies heavily on assessments that are subjective, qualitative and inadequate. Octave Bioscience has developed an integrated Care Platform that consists of several tools to improve measurement capabilities in MS, including a custom assay panel performed using the Olink Platform to quantitatively assess the level of disease activity in blood samples.

The development of this panel involved screening over 1000 protein biomarkers in several deeply phenotyped studies. A dynamic and iterative process that balanced statistical, analytical, and biological factors was then used to select proteins for inclusion in the custom panel. The 21-plex panel has been manufactured and analytically validated in preparation for a forthcoming clinical validation in independent cohorts.

The subject of this webinar was to review the research, development and validation of the custom assay panel.